Customer Stories / Life Sciences / Americas

2020
Bristol Myers Squibb logo

Bristol Myers Squibb Builds Enterprise Data Lakes on AWS

Before moving to the Amazon Web Services (AWS) Cloud, Bristol Myers Squibb was building data lakes using various tools and methods, which created inconsistencies, technical debt, and a higher cost to run. In addition, Bristol Myers Squibb is leveraging AWS Glue to build out a scalable infrastructure with a pay-as-you-go model.  

Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. Before moving to the Amazon Web Services (AWS) Cloud, Bristol Myers Squibb was building data lakes using various tools and methods, which created inconsistencies, technical debt, and a higher cost to run. Brian Zellner, associate director of R&D data lakes at Bristol Myers Squibb, says, “When we moved to AWS, we started with a multi-tenant concept that allows us to use services in a consistent way.”

In addition, Bristol Myers Squibb is leveraging AWS Glue to build out a scalable infrastructure with a pay-as-you-go model, which "gave us great advantage over what we were doing before, so we’re able to ingest data faster and transform it and get faster insights,” says Zellner.

“Speed is a core tenant of what we’re trying to do at Bristol Myers Squibb. The faster that we can develop drugs, the sooner they can get to the patients who need them,” explains Zellner.

kr_quotemark

Speed is a core tenant of what we’re trying to do at Bristol Myers Squibb. The faster that we can develop drugs, the sooner they can get to the patients who need them."

Brian Zellner
Associate Director of R&D Data Lakes, Bristol Myers Squibb

AWS Service Used

Amazon Glue

Discover, prepare, and integrate all your data at any scale.

Learn more »

More Life Sciences Customer Stories

Showing results: 21-24
Total results: 216

no items found 

  • Europe, Middle East, & Africa

    Exscientia Uses Generative AI to Reimagine Drug Discovery

    Exscientia uses generative artificial intelligence (AI) throughout the design-make-test-learn (DMTL) cycle to discover new therapies for patients quickly and relatively inexpensively. Conventional drug discovery methods can take up to 15 years and cost over 2 billion dollars, with an average failure rate of 90–96 percent because scientists hunt for specific drug candidates among 1060 bioavailable small molecules.
    2024
  • United States

    RUSH Creates a Population Health Analytics Platform on AWS

    Rush University System for Health is reducing the life expectancy gap and addressing the social determinants of health with its Health Equity Care & Analytics Platform built on AWS.
    2023
  • United States

    Reinventing Patient Experiences in the Cloud

    Nationwide Children’s Hospital, CalvertHealth, and Rush University System for Health provide seamless patient care using AWS services.

    2023
  • North America

    Siemens on AWS

    Siemens uses an array of AWS services to bring IIOT to railways and factories, developing intelligent infrastructure for buildings and distributed energy systems, implementing AI into its cybersecurity platform, and more.
    2020
1 54

Get Started

Organizations of all sizes across all industries are transforming their businesses and delivering on their missions every day using AWS. Contact our experts and start your own AWS journey today.